MedTrace Logo

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

NCT07748364 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-08-05

No results posted yet for this study

Summary

This trial will enroll patients with relapsed/refractory DLBCL and MCL, with the opportunity to receive single-agent glofitamab as early as the second-line. Patients will have superficially accessible disease to enable core-needle biopsy prior to therapy initiation, and on cycle 1 day 15 and cycle 2 day 1 of therapy administration to enable high throughput molecular profiling of disease and immune dynamics while on treatment.

Conditions

  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • Relapsed/Refractory Mantle Cell Lymphoma

Interventions

BIOLOGICAL

Glofitamab

Glofitamab is a bispecific T-cell-engaging antibody, designed to bind CD20 on B-cells, and CD3 on T-cells, bringing T-cells into close contact with malignant B-cells to trigger immune-mediated killing.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Joshua Brody

    lead OTHER

Principal Investigators

  • Joshua Brody · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748364 on ClinicalTrials.gov